My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.66 +0.37 (+0.66%)

Streaming Delayed Price Updated: 11:20 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

34 35 Next >

The Best Stocks to Invest $20,000 in Right Now ↗

April 23, 2023

You'll want to hold on to these top stocks for the long term.

Via The Motley Fool

Buy the Dip: 2 Top Stocks to Snatch Up Now ↗

April 23, 2023

You don't need to be too gutsy to buy these two stocks while they're down.

Via The Motley Fool

3 Stocks With Huge Catalysts on the Way ↗

April 22, 2023

Big news could mean big boosts for these stocks.

Via The Motley Fool

2 Growth Stocks That Could Keep Growing for Decades ↗

April 21, 2023

These businesses will likely only get larger in the future.

Via The Motley Fool

Better Big Biotech Buy: Biogen vs. Vertex ↗

April 20, 2023

One is slightly cheaper than the other.

Via The Motley Fool

The Top 3 Biotech Stocks to Watch in 2023 ↗

April 20, 2023

Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023.

Via InvestorPlace

Why CRISPR Therapeutics Stock Is Marching Higher Today ↗

April 17, 2023

This gene-editing stock has been heating up over the past week.

Via The Motley Fool

What 14 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

April 17, 2023

Via Benzinga

Is CRISPR Therapeutics Stock a Buy Now? ↗

April 14, 2023

The biotech could soon be a commercial-stage company.

Via The Motley Fool

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗

April 20, 2023

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...

Via Benzinga

3 High-Growth Biotech Stocks Poised for Success in 2023 ↗

April 18, 2023

If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity

Via InvestorPlace

The Top Healthcare Stocks to Buy With $100 ↗

April 18, 2023

A small investment now may bring big results over time.

Via The Motley Fool

Why Shares of Editas Medicine Rose Monday ↗

April 17, 2023

The company is benefiting from positive news affecting other gene-editing stocks.

Via The Motley Fool

Better Growth Stock: Axsome vs. CRISPR Therapeutics ↗

April 16, 2023

These companies are both in the early days of their growth stories.

Via The Motley Fool

CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst ↗

April 13, 2023

Via Benzinga

Why Shares of CRISPR Therapeutics Jumped Thursday ↗

April 13, 2023

An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective.

Via The Motley Fool

Where Will CRISPR Therapeutics Be in 5 Years? ↗

April 09, 2023

Could CRISPR Therapeutics be the next big healthcare stock?

Via The Motley Fool

Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock ↗

April 13, 2023

Shares of CRSP stock are moving higher following an initiation of coverage by Cantor Fitzgerald and continued buys from Cathie Wood.

Via InvestorPlace

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗

April 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

Via InvestorPlace

$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis ↗

April 13, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗

April 13, 2023

Via Benzinga

CRISPR Stock: Bull vs. Bear ↗

April 08, 2023

CRISPR's first approved product may be right around the corner.

Via The Motley Fool

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

2 Nasdaq Growth Stocks That Are Screaming Buys in April ↗

April 13, 2023

Massive drivers of fresh earnings are drawing closer, and risks are declining.

Via The Motley Fool

These Up-and-Coming Stocks Are Screaming Buys Right Now ↗

April 13, 2023

Both companies could deliver revenue and share price growth over the long term.

Via The Motley Fool

Could This Move Make Vertex's Next Blockbuster Even Bigger? ↗

April 12, 2023

Vertex is showing it can branch out beyond its cystic fibrosis specialty.

Via The Motley Fool

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

5 S&P 500 Stocks Showing Strength As Recession Fears Rise ↗

April 07, 2023

Medical stocks are holding up amid economic and market uncertainty.

Via Investor's Business Daily

What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio ↗

April 06, 2023

Both biotechs are aiming for the same markets, but they are not equally risky.

Via The Motley Fool

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗

April 06, 2023

Neither stock is a good choice for those who can't handle a lot of risk.

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.